Public Citizen turns heat back up on pharma pricing with AbbVie attack

26 September 2017

An attack on the US drugmaker AbbVie (NYSE: ABBV) has sought to put the issue of rising drug prices back in the public eye again.

AbbVie was one of four companies praised by the consumer rights advocacy group Public Citizen for agreeing to limit year-on-year price hikes to single digits.

Peter Maybarduk, director of Public Citizen’s Access to Medicine Program, has now published a statement highlighting AbbVie’s apparent failure to stick to that pledge.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK